

Data Sharing Statement

Shah. Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus. *JAMA Oncol*. Published December 20, 2018. 10.1001/jamaoncol.2018.5441

Data

Data available: Yes

Data types: Deidentified participant data, Other (please specify)

Additional Information: clinical study reports

How to access data: Merck & Co., Inc.'s data sharing policy, including restrictions, is available at

http://engagezone.merck.com/ds_documentation.php. Requests for access to the clinical study data can be submitted through the EngageZone site or via email to dataaccess@merck.com.

When available: With publication

Supporting Documents

Document types: None

Additional Information

Who can access the data: Qualified Scientific Researchers

Types of analyses: for a specific purpose outlined in proposal

Mechanisms of data availability: After researcher enters into a standard data sharing agreement and the proposal is approved

Any additional restrictions: Researchers must commit to transparency in publication